Chong Kun Dang traded at 66,300 won on the morning of the 8th, up 100 won from the previous trading day, effectively searching for direction in flat territory. With the gain being modest, the short-term flow appears closer to waiting for new catalysts rather than either buyers or sellers dominating the market.

With the stock price moving in a narrow range, market attention is turning to Chong Kun Dang's earnings growth foundation and R&D pipeline. The brokerage industry views growth in the core business centered on new products and clinical progress of the new drug candidate CKD-510 as medium- to long-term valuation variables.

■ Heungkuk Securities: "New Products to Lead Core Business Growth"... Maintains Target Price of 100,000 Won

Heungkuk Securities projected that expanding sales of new products will lead stable growth in Chong Kun Dang's core business. The firm maintained a 'BUY' rating and a target price of 100,000 won. It positively assessed the company's establishment of a stable revenue growth base in its existing business, separate from current stock price movements.

For pharmaceutical companies' earnings, alongside defending sales of existing flagship products, how quickly new products contribute to revenue is important. Once new products take root in the market, they can reduce dependence on specific products while broadening overall revenue growth. Heungkuk Securities' emphasis on the 'new product topline'—topline referring to a company's revenue—can be read in this context.

■ CKD-510 Clinical Progress as a Variable for Corporate Value Re-rating

Another area drawing market attention is CKD-510. Heungkuk Securities assessed that clinical progress on CKD-510 could be a variable that drives a future re-rating of Chong Kun Dang's corporate value. Stock prices of new drug developers are influenced not only by current earnings but also by the value of their R&D pipelines. As clinical development progresses in stages and the likelihood of commercializing the candidate increases, the market's valuation standards applied to the company may also change.

However, new drug development is a field where unforeseen variables can arise during clinical trials. Therefore, expectations for clinical progress and actual development results need to be viewed separately.

■ Balance of Two Pillars... Key Points to Watch

Chong Kun Dang is drawing attention because its two pillars—the earnings base built through its existing pharmaceutical business and new drug R&D—are moving together. While the existing business supports stable revenue and cash flow, the new drug pipeline can serve as a growth variable determining the potential for further increases in corporate value. Heungkuk Securities' maintenance of the 100,000 won target price is also seen as reflecting this view.

That said, a target price is a figure derived from a securities firm's analysis and assumptions, and does not mean the actual stock price will reach that level. Valuations may change depending on revised earnings outlooks, clinical progress, and investment sentiment in the pharmaceutical and biotech sectors.

In this situation, future earnings changes and R&D progress could become more important variables than daily stock price fluctuations. In particular, key points to watch in the core business are how much new products actually contribute to revenue growth and whether they can drive overall top-line expansion alongside existing product lines. During trading on the 8th, Chong Kun Dang continued moving in flat territory around 66,300 won, but the brokerage industry is focusing on the company's two pillars: its core business and new drug development.

[This article was written for informational purposes and does not recommend buying or selling any specific stock. Securities firms' target prices and earnings forecasts are based on assumptions as of the analysis date and may change depending on future earnings and clinical progress. New drug development involves uncertainties in the clinical process, and actual results may differ from expectations. Investment decisions and responsibilities rest with the investor, and AI assistance was utilized in writing this article.]